Clincosm LogoSign in Get a demo

The Serum Lipid Profiles in ITP: a Retrospective Study

Sponsor
Ming Hou (Other)
Overall Status
Completed
CT.gov ID
NCT05095896
Collaborator
(none)
457
Enrollment
1
Location
35
Actual Duration (Months)
13.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The project was retrospectively undertaking by Qilu Hospital of Shandong University in China. In order to investigate the correlations between platelet indices, serum lipids and bleeding symptoms in ITP.

Condition or Disease Intervention/Treatment Phase
  • Other: ITP patients

Detailed Description

Background: Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disease characterized by increased platelet destruction and impaired thrombopoiesis. Platelet indices changes depending on the morphology and volume of platelets. Serum lipids have been found to affect platelet formation and activity in certain diseases, thus induce the corresponding variation of platelet indices.

Objectives: To investigate the correlations between platelet indices, serum lipids and bleeding symptoms in ITP.

Methods: The clinical data from 457 ITP patients were retrospectively collected and analyzed, including platelet indices, serum lipids, hemorrhage and therapeutic regimen.

Study Design

Study Type:
Observational
Actual Enrollment :
457 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
The Serum Lipid Profiles in Immune Thrombocytopenia: a Retrospective Study
Actual Study Start Date :
Jan 1, 2018
Actual Primary Completion Date :
Dec 1, 2020
Actual Study Completion Date :
Dec 1, 2020

Outcome Measures

Primary Outcome Measures

  1. Platelet count at 1 month after initial therapy [1 month]

    Platelet count was tested at 1 month after initial therapy

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Meet the diagnostic criteria for immune thrombocytopenia.
Exclusion Criteria:
  • (1) receiving platelet transfusion within 7 days or ITP-related medication within 3 months (2) treated with lipid-lowing agents, including statins, fibrates, niacin, bile sequestrant resins, ezetimibe and so on.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Qilu hospital of Shandong university Jinan Shandong China 273300

Sponsors and Collaborators

  • Ming Hou

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ming Hou, Manager, Shandong University
ClinicalTrials.gov Identifier:
NCT05095896
Other Study ID Numbers:
  • lipid in ITP
First Posted:
Oct 27, 2021
Last Update Posted:
Oct 27, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ming Hou, Manager, Shandong University
immune thrombocytopenia
Additional relevant MeSH terms:
Thrombocytopenia
Purpura, Thrombocytopenic, Idiopathic

Study Results

No Results Posted as of Oct 27, 2021